Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application.
Physical Activity Behavior Change in Persons With Neurologic Disorders: Overview and Examples From Parkinson Disease and Multiple Sclerosis.
Zebrafish screen identifies novel compound with selective toxicity against leukemia.
Distinct profiles of myelin distribution along single axons of pyramidal neurons in the neocortex.
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Multiple sclerosis: a primary care perspective.
Disease-modifying therapies in Chinese children with multiple sclerosis.
Systematic approaches to central nervous system myelin.
Oligoclonal band and multiple sclerosis risk in monosymptomatic optic neuritis patients: a retrospective study of 84 patients.
Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain.
RNF and Betaseron® Tolerability Study (REFORMS)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Development of a Computer-aided Diagnostic System for Detecting Multiple Sclerosis Using Magnetic Resonance Images.
The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes.
Brain Hemodynamic Changes Associated with Chronic Cerebrospinal Venous Insufficiency Are Not Specific to Multiple Sclerosis and Do Not Increase Its Severity.
Deep 3D Convolutional Encoder Networks with Shortcuts for Multiscale Feature Integration Applied to Multiple Sclerosis Lesion Segmentation.
Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.
Multiple sclerosis associated with Leber's Hereditary Optic Neuropathy.
Multiplexing analysis of the polyspecific intrathecal immune response in multiple sclerosis.
Recent Gains in Clinical Multiple Sclerosis Research Review.
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE)
Over six cups of coffee a day may reduce the risk of developing multiple sclerosis.
Multiple Sclerosis: Validation of MR Imaging for Quantification and Detection of Iron.
Pages
« first
‹ previous
…
168
169
170
171
172
173
174
175
176
…
next ›
last »